{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-25-000946","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.637397+00:00","generated_at":"2026-05-18T13:49:33.005935+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Arcturus ARCT-810 Phase 2 interim: glutamine normalized, ureagenesis improved (p=0.026)","bullets":["Combined Phase 2 data show glutamine significantly reduced (p=0.0055); levels normalized after 3 doses in US study.","15N-ureagenesis function (RUF) increased from 29.0% baseline to 43.7% at day 28 post-fifth dose (p=0.026).","Ammonia remained stable and within normal range in both studies; one hyperammonemia event on placebo.","ARCT-810 safe and well tolerated across Phase 1/2 with no serious infusion reactions on optimized 3-hour regimen."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-25-000946","json":"https://secwatch.observer/filing/0001193805-25-000946.json","markdown":"https://secwatch.observer/filing/0001193805-25-000946.md","text":"https://secwatch.observer/filing/0001193805-25-000946.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/0001193805-25-000946-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380525000946/e664658_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T13:49:33.005935+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}